Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eprosartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eprosartan SCHEMBL1815060 | 1.00 | AGTR1 (1.00) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL4026 | 1.00 | AGTR1 (1.00) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL4025 | 1.00 | AGTR1 (1.00) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL7405237 | 0.99 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1119964 | 0.99 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1119965 | 0.99 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL7405236 | 0.99 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1897811 | 0.99 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL6747994 | 0.99 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL6747993 | 0.99 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276166-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | UNIV CALIFORNIA (US) | 2020-09-03 | — | — | US | claimed |
| US-20160367530-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-12-22 | — | — | US | claimed |
| US-20130066252-A1 | METHOD FOR DIAGNOSIS FOR MULTIPLE SCLEROSIS INVOLVING ANTI1-RECEPTOR ANTIBODY | CELLTREND GMBH (DE) | 2013-03-14 | — | — | US | claimed |
| US-20120058949-A1 | Methods of Treating Neurological Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-03-08 | — | — | US | claimed |
| US-20100098688-A1 | METHOD FOR DIAGNOSIS OF A DISEASE INVOLVING AN ANTI-AT1-RECEPTOR ANTIBODY | CELLTREND GMBH (DE) | 2010-04-22 | — | — | US | claimed |
| EP-1884775-A1 | Method for diagnosis of a disease involving an anti-AT1-receptor antibody | Celltrend GmbH (DE) | 2008-02-06 | — | — | EP | claimed |
| US-20200276166-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | UNIV CALIFORNIA (US) | 2020-09-03 | — | — | US | disclosed |
| US-10668049-B2 | Methods of treating cognitive decline with transforming growth factor beta inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-06-02 | — | — | US | disclosed |
| US-20160367530-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-12-22 | — | — | US | disclosed |
| US-9468649-B2 | Methods of treating epilepsy with transforming growth factor beta inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-18 | — | — | US | disclosed |
| EP-2558856-B1 | METHOD FOR DIAGNOSIS OF MULTIPLE SCLEROSIS INVOLVING ANTI-AT1-RECEPTOR ANTIBODY | CELLTREND GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-20160081901-A1 | COMPOSITIONS AND METHODS FOR HAIR GROWTH | WUHAN OPTICS VALLEY BRIDGEBIOMED INTERNATIONAL CORPORATION (CN) | 2016-03-24 | — | — | US | disclosed |
| US-20150119329-A1 | MODULATION OF ANGIOTENSIN II RECEPTORS FOR THE PREVENTION AND TREATMENT OF MALARIA CEREBRAL | NEW YORK UNIVERSITY (US) | 2015-04-30 | — | — | US | disclosed |
| US-20100331356-A1 | SELF-MICROEMULSIFYING DRUG DELIVERY SYSTEMS | LEK PHARMACEUTICALS D.D. (SI) | 2010-12-30 | — | — | US | disclosed |
| US-7858611-B2 | Neurogenesis by modulating angiotensin | BRAINCELLS INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100098688-A1 | METHOD FOR DIAGNOSIS OF A DISEASE INVOLVING AN ANTI-AT1-RECEPTOR ANTIBODY | CELLTREND GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
| EP-2021000-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | Braincells, Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| EP-1884775-A1 | Method for diagnosis of a disease involving an anti-AT1-receptor antibody | Celltrend GmbH (DE) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007134136-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081901-A1 | COMPOSITIONS AND METHODS FOR HAIR GROWTH | AGTR2, AGTR1, BDKRB2 | AGTR1 2/4885ABCC3 3693/4885ABCC2 3119/4885 |
| US-20150119329-A1 | MODULATION OF ANGIOTENSIN II RECEPTORS FOR THE PREVENTION AND TREATMENT OF MALARIA CEREBRAL | AGTR2, AGTR1, ACE2 | AGTR1 2/4885ABCC3 845/4885ABCC2 494/4885 |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | AGTR1 8/4885ABCC3 4434/4885ABCC2 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.